Search PubMed⌕ Search

Biomedical subjects

T Torigoe

Publications and source records attributed to T Torigoe.

At least 109 records · Page 6Linked to original sources
PubMed1981

Survey of cord blood hemoglobin in Japan and identification of two new gamma chain variants.

Two gamma chain variants were discovered during a survey of 2,569 cord bloods of Japanese. One was the first case with mutation of the T-gamma chain, i. e. Hb F Yamaguchi or gamma 80 (EF 4) Asp leads to Asn (75 Thr, 136 Ala). It comprised 33.6% of Hb F, an unusually high percentage for a gamma chain variant. The other concerned with the first report of substitution at E 16, i. e. Hb F Iwata or gamma 72 (E 16) Gly leads to Arg (75 Ile, 136 Ala). It comprised 11.0% which is comparable to the values usually reported in an A-gamma chain variant. No clinical consequences have been observed in association with the hemoglobin variants.

Amino Acid Sequence↗
PubMed1980

Effects of domperidone on serum prolactin levels in human beings.

Effects of domperidone, a dopaminergic antagonist, on serum prolactin levels were studied in 6 normal men and 6 normal cyclic women at the different phases of their menstrual cycles (i.e., the follicular, the preovulatory and the luteal phases). Domperidone (10 mg, i.v.) caused significant increases in serum prolactin in all cases within 15 min after the injection. The prolactin response was significantly (p < 0.01) higher in women than in men, and there was no significant difference in the prolactin responses among the three phases of the menstrual cycles. These results indicate that domperidone may be an effective stimulator of serum prolactin secretion in human beings.

Adult↗
PubMed1979

Tumor antigen of human cervical squamous cell carcinoma: correlation of circulating levels with disease progress.

A double-antibody radioimmunoassay method was used for serial determinations of a tumor-antigen (TA-4) of cervical squamous cell carcinoma, and the correlation of serum antigen levels with the disease progess was investigated in 23 patients with cervical squamous cell carcinoma. Ten cases with widespread metastases received radiotherapy and/or chemotherapy. Nine of these cases who showed progression of the disease had a corresponding increase in serum antigen levels, while one case who had regression of the disease showed a corresponding decrease in serum antigen levels. Thirteen patients received radical surgery, and in all of these, high pretreatment antigen levels declined to undetectable levels 1 or 2 weeks after surgery. A panel of coded sera from the NCI-Mayo Clinic Serum Bank was also studied for evaluating the specificity of the assay. Thirteen of 25 patients (52%) with cervical squamous cell carcinoma showed positive serum antigen levels, while only one of 58 control cases (1.7%) showed false-positive result. These results suggest that serial TA-4 determinations may provide a useful method for evaluating regression or progression of the disease.

Adult↗
PubMed1977

Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma.

A heterologous antiserum for human cervical squamous cell carcinoma was prepared and specificity determined by Ouchterlony immunodiffusion and immunofluorescence studies. With this antiserum, a tumor antigen was purified from human cervical squamous cell carcinoma tissue. The specificities of the antigen and the antiserum were then re-examined by a radioimmunoassay method using 125 I-labeled purified antigen. Although normal cervical tissue extract showed a moderate cross-reactivity in the radioimmunoassay, the circulating antigen activity could not be detected in normal women or in several patients with carcinomas, whereas 27 of 35 patients with cervical squamous cell carcinoma showed detectable serum antigen activity. All aptients with advanced stages of cervical squamous cell carcinoma showed detectable antigen levels. These results indicate that there is a quantitative abnormality, at least, of this tumor antigen in patients with cervical squamous cell carcinoma and that the radioimmunoassay for the antigen is a potentially useful tool in clinical care.

Antibody Specificity↗